biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > On the positive side...

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 16, 2022 12:37pm

105 Views

Post# 35176075

RE:On the positive side...

Great trading opportunity for you, eh, pof?

Loading up at 6¢ and 7¢ are ya?

So if it goes way back up to 10¢, will the deal be so hot for you?

Or do you expect 12¢?

I hope the deal turns out great, but it will take a year or two to find out. It could go south far sooner though.

Get ready to bet the downside, pof. It'll come right out of the blue, no warning.

"Biodexa today announced the sale of its TransNeural BBB platform, formerly xB3, to the DrDR Smokin' Vencap, a private venture fund. The deal, worth $25 million plus a 1% royalty on net Smokin' sales, will help fund Biodexa's clinical programs, already underway."

jd

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages